Phase 3 Clinical Trials in 2024

2024 Phase 3 Research Overview

Phase 3 clinical trials started in 2024 provide a snapshot of the medical research landscape. In total, 68 such trials were initiated. 51 of these are still actively recruiting. 1 trials have been completed. Leading sponsors include Merck Sharp & Dohme LLC, Janssen Research & Development, LLC, AstraZeneca.

68

Phase 3 Trials

51

Recruiting

10

Sponsors

Trial Status

RECRUITING: 51 trials
ACTIVE NOT RECRUITING: 13 trials
TERMINATED: 2 trials
ENROLLING BY INVITATION: 1 trial
COMPLETED: 1 trial

Top Sponsors (2024)

Merck Sharp & Dohme LLC (7 trials)
Janssen Research & Development, LLC (5 trials)
AstraZeneca (5 trials)
Boehringer Ingelheim (5 trials)
National Cancer Institute (NCI) (5 trials)
Washington University School of Medicine (3 trials)
Novo Nordisk A/S (3 trials)
Novartis Pharmaceuticals (3 trials)
AbbVie (2 trials)
89bio, Inc. (2 trials)

Phase 3 Trials Started in 2024

A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder

NCT06564818 · RECRUITING · Phase 3 · Cybin IRL Limited

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

NCT06741228 · ACTIVE NOT RECRUITING · Phase 3 · Definium Therapeutics US, Inc.

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors

NCT06382948 · RECRUITING · Phase 3 · MedSIR

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults With Moderate to Severe Sjogren's Disease (SjD)

NCT06741969 · ACTIVE NOT RECRUITING · Phase 3 · Janssen Research & Development, LLC

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245 · RECRUITING · Phase 3 · OSE Immunotherapeutics

A Randomized, Open-Label, Multicenter, Phase III Clinical Study of SKB264 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06670196 · RECRUITING · Phase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

NCT06635824 · ACTIVE NOT RECRUITING · Phase 3 · Genmab

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

NCT06647498 · RECRUITING · Phase 3 · Washington University School of Medicine

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

NCT05552157 · RECRUITING · Phase 3 · Washington University School of Medicine

A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater

NCT06698042 · ACTIVE NOT RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

NCT06692738 · RECRUITING · Phase 3 · AstraZeneca

A Prospective, Randomized, Standard of Care Controlled, Parallel, Open-Label, Multicenter Pivotal Study to Evaluate the Efficacy and Safety of Avastin® in Combination With NaviFUS System Compared With Avastin® Alone for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT06496971 · RECRUITING · Phase 3 · NaviFUS Corporation

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

NCT06632457 · RECRUITING · Phase 3 · Boehringer Ingelheim

Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes

NCT06246799 · RECRUITING · Phase 3 · The University of Texas Health Science Center at San Antonio

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

NCT06534411 · ACTIVE NOT RECRUITING · Phase 3 · Novo Nordisk A/S

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

NCT06217302 · RECRUITING · Phase 3 · Alessandro Doria

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

NCT06162715 · ENROLLING BY INVITATION · Phase 3 · Vanderbilt University Medical Center

A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises

NCT06439082 · RECRUITING · Phase 3 · Novartis Pharmaceuticals

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

NCT06623422 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

NCT06417814 · RECRUITING · Phase 3 · AstraZeneca

A Randomized Clinical Trial to Define the Best Strategy for the Management of Heart Failure and Chronic Kidney Disease Among Elderly Patients With or at High Risk of hyperKalemia in Span by Optimizing the Use of RAASi With SZC

NCT06578078 · RECRUITING · Phase 3 · Fundación para la Investigación del Hospital Clínico de Valencia

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

NCT06492616 · RECRUITING · Phase 3 · Stemline Therapeutics, Inc.

A Phase IIIb Single Arm, 2 Cohorts Study Assessing the Efficacy and Safety of Capivasertib+ Fulvestrant as Treatment for Locally Advanced(Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With Endocrine Therapy in Chinese Patients

NCT06635447 · ACTIVE NOT RECRUITING · Phase 3 · AstraZeneca

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

NCT06635135 · TERMINATED · Phase 3 · Janssen Research & Development, LLC

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

NCT06632444 · RECRUITING · Phase 3 · Boehringer Ingelheim

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

NCT06422806 · RECRUITING · Phase 3 · National Cancer Institute (NCI)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314 · RECRUITING · Phase 3 · Akero Therapeutics, Inc

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

NCT06058585 · RECRUITING · Phase 3 · The George Institute

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897 · RECRUITING · Phase 3 · AbbVie

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

NCT06531824 · RECRUITING · Phase 3 · Boehringer Ingelheim

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

NCT06467357 · RECRUITING · Phase 3 · AstraZeneca

A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer

NCT06519370 · ACTIVE NOT RECRUITING · Phase 3 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

A Randomized Controlled Phase III Study of Adaptive Hypofractionated Radiotherapy Combined With Concurrent Chemotherapy and Consolidative Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer Based on Dynamic Enhanced Magnetic Resonance Imaging

NCT06545747 · RECRUITING · Phase 3 · Sun Yat-sen University

A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms

NCT06559306 · RECRUITING · Phase 3 · Janssen Research & Development, LLC

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

NCT06096844 · RECRUITING · Phase 3 · National Cancer Institute (NCI)

Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)

NCT06530732 · RECRUITING · Phase 3 · Zhejiang Provincial People's Hospital

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open Label Long-term Extension Treatment With Aticaprant

NCT06514742 · TERMINATED · Phase 3 · Janssen Research & Development, LLC

A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549 · RECRUITING · Phase 3 · UCB Biopharma SRL

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

NCT06203600 · RECRUITING · Phase 3 · National Cancer Institute (NCI)

EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

NCT06424288 · RECRUITING · Phase 3 · Boehringer Ingelheim

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)

NCT06389136 · RECRUITING · Phase 3 · AbbVie

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

NCT06305754 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

NCT06422143 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease

NCT06384573 · ACTIVE NOT RECRUITING · Phase 3 · Washington University School of Medicine

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

NCT06419374 · RECRUITING · Phase 3 · 89bio, Inc.

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

NCT06345729 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

NCT06351631 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

NCT06295731 · ACTIVE NOT RECRUITING · Phase 3 · Inhibrx Biosciences, Inc

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 · RECRUITING · Phase 3 · AstraZeneca

A Randomized, Double-blind, Parallel-group Study to Compare Efficacy, Safety, and Immunogenicity of GME751 (Proposed Pembrolizumab Biosimilar) and EU-authorized Keytruda® in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT06159790 · COMPLETED · Phase 3 · Sandoz

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study

NCT06303739 · ACTIVE NOT RECRUITING · Phase 3 · University of North Carolina, Chapel Hill

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

NCT06172296 · RECRUITING · Phase 3 · National Cancer Institute (NCI)

A Phase 3b, Open-label, Multicenter Study to Evaluate Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935 · ACTIVE NOT RECRUITING · Phase 3 · Janssen-Cilag Ltd.

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

NCT06312176 · RECRUITING · Phase 3 · Merck Sharp & Dohme LLC

Comparison of Stereotactic Body Radiotherapy and Selective Internal Radiation Therapy in Combination With Immunotherapy for Locally-advanced, Unresectable Hepatocellular Carcinomas: an Open-label, Randomized Controlled Trial (BIIRTH)

NCT07293468 · RECRUITING · Phase 3 · Tuen Mun Hospital

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

NCT06200207 · RECRUITING · Phase 3 · Novo Nordisk A/S

Improving Outcomes in Depression in Primary Care in a Low Resource Setting

NCT05944926 · RECRUITING · Phase 3 · Harvard Medical School (HMS and HSDM)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06318169 · RECRUITING · Phase 3 · 89bio, Inc.

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

NCT06308653 · ACTIVE NOT RECRUITING · Phase 3 · Usona Institute

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease

NCT05923073 · RECRUITING · Phase 3 · Janssen Research & Development, LLC

A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease

NCT05509777 · RECRUITING · Phase 3 · Eli Lilly and Company

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

NCT05939414 · RECRUITING · Phase 3 · Novartis Pharmaceuticals

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

NCT05827081 · RECRUITING · Phase 3 · Novartis Pharmaceuticals

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

NCT06151574 · RECRUITING · Phase 3 · Boehringer Ingelheim

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

NCT06152575 · RECRUITING · Phase 3 · Pfizer

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

NCT05987241 · RECRUITING · Phase 3 · National Cancer Institute (NCI)

The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis

NCT06231758 · RECRUITING · Phase 3 · Mostafa Bahaa

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

NCT06221969 · ACTIVE NOT RECRUITING · Phase 3 · Novo Nordisk A/S

Frequently Asked Questions

How many Phase 3 trials started in 2024?

68 Phase 3 clinical trials were started in 2024 according to ClinicalTrials.gov data tracked by ReadTheTrial.

What is Phase 3 in clinical trials?

Phase 3 trials are large-scale pivotal studies with 300-3,000+ participants for FDA approval.

Are any 2024 Phase 3 trials recruiting?

Yes, 51 Phase 3 trials from 2024 are still recruiting.

Explore More